Skip to main content
. Author manuscript; available in PMC: 2017 Dec 1.
Published in final edited form as: Mol Cancer Ther. 2016 Sep 26;15(12):2853–2862. doi: 10.1158/1535-7163.MCT-15-0789

Fig. 1. Growth and survival of Igrov1 and Igrov1/T8 cells in the presence of TPT.

Fig. 1

(A) Igrov1 and Igrov1/T8 cells were incubated in the presence of 950 nM TPT and percent confluency was estimated under light microscopy over a period of 14 days. The resistant cells were split on day 7 due to cellular overgrowth. The average values with standard deviation are shown; n=3. (B) Igrov1 and Igrov1/T8 cells were incubated in the presence of 0 nM, 3 nM (Igrov1), 10 nM, 30 nM, 100 nM, 300 nM, 1 μM (Igrov1/T8), and 3 μM concentration of TPT. The cells in each concentration were counted on day 7 and the percent viability of the cells at each concentration was calculated normalizing to the cell count at 0 nM TPT. The EC50 was extrapolated by fitting the data to a sigmoidal dose response curve. Average values with standard deviation are shown; n=2.